The Role of Rituximab in the Therapy of Mixed Cryoglobulinemia

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-88-470-1705-4_38
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term efficacy of rituximab in hepatitis C virus-associated cryoglobulinemia

  2010cited by this paper
• Rituximab in cryoglobulinemic peripheral neuropathy

  2009cited by this paper
• Successful combination of Rituximab and plasma exchange in the treatment of cryoglobulinemic vasculitis with skin ulcers: a case report

  2009cited by this paper
• Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.

  2009cited by this paper
• Catastrophic multiple organ ischemia due to an anti‐Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab

  2009cited by this paper
• Hepatitis C virus-induced cryoglobulinemia.

  2009cited by this paper
• Pathophysiological aspects of memory B-cell development.

  2008cited by this paper
• Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis

  2008cited by this paper
• Disappearance of bone marrow B cell clonal expansion in patients with type II hepatitis C virus-related cryoglobulinemic glomerulonephritis after clinical efficient rituximab therapy

  2008cited by this paper
• Rituximab as a Therapeutic Tool in Severe Mixed Cryoglobulinemia

  2008cited by this paper
• Efficacy of low-dose rituximab for mixed cryoglobulinemia.

  2007cited by this paper
• Rapidly Fatal Acanthamoeba Encephalitis and Treatment of Cryoglobulinemia

  2007cited by this paper
• Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF).

  2007cited by this paper
• Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease.

  2007cited by this paper
• B-cell depletion in the treatment of mixed cryoglobulinemia.

  2007cited by this paper
• Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients.

  2006cited by this paper
• Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.

  2006cited by this paper
• Lack of efficacy of Rituximab in a patient with essential mixed cryoglobulinaemia.

  2006cited by this paper
• Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia.

  2005cited by this paper
• Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab.

  2005cited by this paper
• Rituximab Therapy for De Novo Mixed Cryoglobulinemia in Renal Transplant Patients

  2005cited by this paper
• Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response

  2004cited by this paper
• Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure.

  2004cited by this paper
• Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.

  2004cited by this paper
• Extrasalivary lymphoma development in Sjögren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering.

  2003cited by this paper
• Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20.

  2003cited by this paper
• Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis

  2003cited by this paper
• Efficacy and safety of rituximab in type II mixed cryoglobulinemia.

  2003cited by this paper
• Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.

  2002cited by this paper
• Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)

  2002cited by this paper
• Rituximab for the treatment of type II mixed cryoglobulinemia.

  2002cited by this paper
• Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia.

  2000cited by this paper
• Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis.

  2000cited by this paper
• Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

  2000cited by this paper
• Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

  2000cited by this paper
• Prevalence of Monoclonal Gammopathies in Patients with Hepatitis C Virus Infection

  1998cited by this paper
• IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

  1997cited by this paper
• Extrahepatic manifestations of hepatitis C.

  1996cited by this paper
• Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia.

  1996cited by this paper
• Hepatitis C virus and non-Hodgkin's lymphomas.

  1996cited by this paper
• Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias.

  1995cited by this paper
• Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

  1994cited by this paper

• No citing papers are available for this paper.